Grape King Bio Ltd
Research Grape King Bio Ltd (1707.TW) on Bullrun: market cap TWD 12.93B, P/E 11.4, dividend yield 7.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1707.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyTWD
- Market capTWD 12.93B
- P/E11.4
- Dividend yield7.6%
- Financial periodQ2 2026
- RevenueTWD 2.41B
- Net incomeTWD 232.25M
- Free cash flowTWD 230.93M
- Gross margin73.2%
Valuation Snapshot
latest market cap is TWD 12.93B; P/E is 11.4; dividend yield is 7.6%.
Peer valuation comparison
Latest P/E is 11.35x versus a Healthcare sector median of 21.8x (47.9% below).
Latest dividend yield is 7.62% versus a Healthcare sector median of 2.4% (217.5% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 12.93B | 11.4 | 6.9% | 6 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 6 TWD, yield 7.6%.
About Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes.
ETFs that hold Grape King Bio Ltd
US-listed ETFs
Grape King Bio Ltd is held by 20 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | <0.01% | 0.09% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Grape King Bio Ltd's market cap?
Grape King Bio Ltd's market capitalization is TWD 12.93B.
What is Grape King Bio Ltd's P/E ratio?
Grape King Bio Ltd's price-to-earnings (P/E) ratio is 11.4.
Does Grape King Bio Ltd pay a dividend?
Grape King Bio Ltd has a dividend yield of 7.6%.
What does Grape King Bio Ltd do?
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes.